Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a study of a new medication for the treatment of cognitive impairments (thinking
difficulties) and negative symptoms in people with schizophrenia. The new medication is
rasagiline. Rasagiline is a drug which has been approved by the Food and Drug Administration
for the treatment of Parkinson's disease. It is used to treat cognitive problems.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore